- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05531799
Anal HSIL Screening Algorithm (0007/65)
Optimizing an Anal High-grade Squamous Intraepithelial Lesion Screening Algorithm for Thai Men Who Have Sex With Men and Transgender Women
Study Overview
Status
Intervention / Treatment
Detailed Description
I. PREPARATION PHASE Purpose To lay groundwork for optimization of anal high-grade squamous intraepithelial lesion screening algorithm for MSM, and identify which test and component(s) should be included in the anal HSIL screening algorithm.
II. OPTIMIZATION PHASE Purpose To form an anal high-grade squamous intraepithelial lesion screening algorithm that meets the optimization criteria.
III. EVALUATION PHASE Purpose To establish whether the optimized anal high-grade squamous intraepithelial lesion screening algorithm has a statistically significant effect on service uptake among MSM compared to the standard of care.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nittaya Phanuphak, MD,PhD.
- Phone Number: 661 825 3544
- Email: nittaya.p@ihri.org
Study Contact Backup
- Name: Siriporn Nonenoy, RN.MPH.
- Phone Number: 661 818 4143
- Email: siriporn.n@ihri.org
Study Locations
-
-
Bangkok
-
Pathum wan, Bangkok, Thailand, 10330
- Recruiting
- Institute of HIV Research and Innovation
-
Contact:
- Nittaya Phanuphak, MD.,Ph.D.
- Phone Number: +66 2 1605371
- Email: nittaya.p@ihri.org
-
Contact:
- Napasawan Chinlaertworasiri
- Phone Number: +66 2 1605371
- Email: napasawan@ihir.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
Clients for MSM and TGW:
- Thai nationality, men with self-identifies as MSM and/or TGW
- HIV-positive MSM/TGW aged 30 years or older or
- HIV-negative MSM/TGW aged 40 years or older
Clinic staff:
- Has worked in the study clinic during phase III
Government stakeholders:
- Involved in health policy development in Thailand
Exclusion criteria
Clients for MSM and TGW:
- Unable to perform any study procedures, or unable to commit to attend all study visits.
- Had Anal cancer lesion at enrollment visit, this exclusion for participation in phase II study.
Clinic staff:
- Not willing to participate in the evaluation
Government stakeholders:
- Not willing to participate in the evaluation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Group 1 DARE/CYTOLOGY/HPV/HRA
Participant request physician assessment for Digital anal rectal exam, Anal cytology, Anal HPV test and High resolution anoscopy for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Group 2 DARE/CYTOLOGY/HPV
Participant request physician assessment for Digital anal rectal exam, Anal cytology, Anal HPV test for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Group 3 DARE/CYTOLOGY/HRA
Participant request physician assessment for Digital anal rectal exam, Anal cytology and High resolution anoscopy for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Group 4 DARE/CYTOLOGY
Participant request physician assessment for Digital anal rectal exam, Anal cytology for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Group 5 DARE/HPV/HRA
Participant request physician assessment for Digital anal rectal exam, Anal HPV test and High resolution anoscopy for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Group 6 DARE/HPV
Participant request physician assessment for Digital anal rectal exam and Anal HPV test for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Group 7 DARE/HRA
Participant request physician assessment for Digital anal rectal exam and High resolution anoscopy for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Group 8 DARE
Participant request physician assessment for Digital anal rectal exam for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Self-collection CYTOLOGY/HPV
Participant request Self-sampling collection for Anal cytology and Anal HPV test for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Self-collection CYTOLOGY
Participant request Self-sampling collection for Anal cytology for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Self-collection HPV
Participant request Self-sampling collection for Anal HPV test for every 6 months within 12 months period
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
Other: Self-collection control group CYTOLOGY/HPV
Participant request Self-sampling collection for Anal cytology and Anal HPV only at month 12
|
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could - identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify new cases of anal HSIL by Anal HSIL screening algorithm
Time Frame: 18 months
|
identify anal HSIL in at least 20% of HIV-positive MSM/TGW and 10% of HIV-negative MSM/TGW within visit schedule.
|
18 months
|
Compare anal HSIL screening method to new anal HSIL screening method algorithm
Time Frame: 24 months
|
Evaluate anal HSIL screening method uptake among MSM/TGW clients in the clinic compare to the implementation of the new anal HSIL screening method algorithm.
|
24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nittaya Phanuphak, MD,PhD., Institute of HIV Research and Innovation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Cervical Diseases
- Uterine Diseases
- Precancerous Conditions
- Neoplasms, Squamous Cell
- Uterine Cervical Dysplasia
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Carcinoma in Situ
- Carcinoma, Squamous Cell
- Squamous Intraepithelial Lesions of the Cervix
Other Study ID Numbers
- IHRI013
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal High-grade Squamous Intraepithelial Lesion
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedHigh Grade Anal Canal Intraepithelial Neoplasia | High Grade Vulvar Squamous Intraepithelial LesionUnited States
-
David FinchLancashire Teaching Hospitals NHS Foundation TrustNot yet recruitingAnal Intraepithelial Neoplasia | Anal High-grade Squamous Intraepithelial Lesion | Anal HSIL
-
Muğla Sıtkı Koçman UniversityCompletedOxidative Stress | Low Grade Squamous Intraepithelial Lesion | High-Grade Squamous Intraepithelial LesionsTurkey
-
National Cancer Institute (NCI)CompletedCervical Cancer | High-grade Squamous Intraepithelial Lesion | Atypical Squamous Cells of Undetermined Significance | Low-grade Squamous Intraepithelial LesionUnited States
-
Medtronic - MITGCompletedAnal Intraepithelial Neoplasia (AIN) | High-grade Squamous Intraepithelial Lesions (HSIL)United States
-
Baylor College of MedicineMedical University of South Carolina; M.D. Anderson Cancer Center; The University... and other collaboratorsActive, not recruitingAnal High Grade Squamous Intraepithelial LesionUnited States
-
Inovio PharmaceuticalsCompletedCervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSILUnited States, Spain, Lithuania, Estonia, South Africa, Argentina, Brazil, Finland, Poland, Puerto Rico
-
Peking University People's HospitalHangzhou Newhorizon Health Technology Co., Ltd.; Hangzhou Mingze Medical Research... and other collaboratorsRecruitingCervical Cancer | Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Human Papillomavirus Infection | Human Papilloma Virus | Adenocarcinoma in Situ | High-Grade Squamous Intraepithelial Lesions | Cervical Intraepithelial Neoplasia Grade II | Cervical Intraepithelial Neoplasia, Grade III | Atypical... and other conditionsChina
-
National Cancer Institute (NCI)TerminatedHuman Papillomavirus | HPV-16 | High Grade Squamous Intraepithelial LesionUnited States
-
University of Witwatersrand, South AfricaMerck Sharp & Dohme LLCCompletedCervical High Grade Squamous Intraepithelial Lesion
Clinical Trials on OPTIMIZATION PHASE
-
University Hospital, Gentofte, CopenhagenRigshospitalet, Denmark; Lund University HospitalUnknownHeart Failure | Ischemic CardiomyopathyDenmark, Sweden
-
MicroPort CRMCompleted
-
Shirley Ryan AbilityLabUniversity of California, Los AngelesRecruiting
-
MicroPort CRMSorin CRMUnknownHeart Failure NYHA Class III and Ambulatory IVUnited States, Spain, United Kingdom, Germany, Italy, Australia, Netherlands, Portugal, France, Austria, Switzerland, Slovenia
-
Fondation Ophtalmologique Adolphe de RothschildTerminatedOcclusion or Malformation of a Cerebral VesselFrance
-
University Hospital DubravaCompletedHypotension During SurgeryCroatia
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Infections | Pregnancy Related | Pre-Exposure ProphylaxisKenya
-
Claude Bernard UniversityCompleted
-
Evangelical Hospital DüsseldorfUniversity Hospital, EssenRecruitingAtrial FibrillationGermany
-
Universita di VeronaCompleted